TY  - JOUR
AU  - Pavel, Marianne
AU  - Gross, David J
AU  - Benavent, Marta
AU  - Perros, Petros
AU  - Srirajaskanthan, Raj
AU  - Warner, Richard R P
AU  - Kulke, Matthew H
AU  - Anthony, Lowell B
AU  - Kunz, Pamela L
AU  - Hörsch, Dieter
AU  - Weickert, Martin O
AU  - Lapuerta, Pablo
AU  - Jiang, Wenjun
AU  - Kassler-Taub, Kenneth
AU  - Wason, Suman
AU  - Fleming, Rosanna
AU  - Fleming, Douglas
AU  - Garcia-Carbonero, Rocio
PY  - 2018
DO  - 10.1530/ERC-17-0455
UR  - http://hdl.handle.net/10668/12005
T2  - Endocrine-related cancer
AB  - Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs)....
LA  - en
KW  - 5-HIAA
KW  - carcinoid syndrome
KW  - metastatic neuroendocrine tumor
KW  - serotonin
KW  - somatostatin analog
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Diarrhea
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Hydroxyindoleacetic Acid
KW  - Male
KW  - Malignant Carcinoid Syndrome
KW  - Middle Aged
KW  - Phenylalanine
KW  - Pyrimidines
KW  - Somatostatin
KW  - Treatment Outcome
TI  - Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
TY  - research article
VL  - 25
ER  -